AnGes website announces trial start date and estimates a $ 5 billion annual market if approved.
It should be no longer than 3 weeks that we get an earnings report and update. A milestone payment from Astellas for the launch of Solid Organ Transplant CMV vaccine test would be great news that could drive more upside to the stock as it would almost surely cause the quarter to be cash flow positive. The earnings update will also serve shareholders well if the sites of the Herpes trial are disclosed so the market can assume the trial is going to happen ASAP. The biggest game changing surprise would be a deal on a universal CMV vaccine. Second big possible upside surprise would be a good deal on the VaxFectin adjuvant. Third good upside surprise would be a BOD deal with investment bankers to sell the company. Fourth would be Vijay deciding to spend more time with his family and turning over the reigns at Vical to a new CEO.
The big disappointment is the inept management team and Board of Directors that isn't focused on wealth creation for shareholders. Vical needs to make a CyMVectin deal or a Vaxfectin deal that produces some value. They should also open up about where the Herpes tests will be conducted so as to build credibility for their future programs. A-7 shredded Vijay and Vical credibility. EVERYTHING they do should be devoted to restoration of credibility as that is what will cause the stock to be valued based on potential. We are punished by bad management that hasn't faced any consequence.
AnGes has also announced a cancer treatment that shuts down blood vessel formation to cancerous tumors. They don't talk about the delivery platform in their news release but I would expect them to use Vical just as they do for Collategene.
On the Collategene front, the Japanese program you quote PM Abe on is just like the Breakthrough Drug Program in the U.S. It would not be a shock to see Collategene get breakthrough designation in both countries. It would be good for each nation to show this level of cooperation to speed a product attacking diabetes to market.
In an award that nobody ever competes for, Vijay Samant of San Diego’s Vical Inc. (Nasdaq: VICL) was named on Tuesday as the worst biotech CEO of 2013 by the stock market website The Street.
The annual award, partly based on a poll of The Street’s readers, was based on delays surrounding the release of the phase 3 results of Vical’s drug allovectin, meant to treat skin cancer.
Adam Feuerstein, senior columnist at The Street, writes that analysis of the study was delayed for years until the company finally announced in August that the results were negative. The day the announcement was made, the company lost more than half its stock value, dropping from $3.58 to $1.53 per share, prompting a string of lawsuits.
But worse was to follow. The company waited three months -- until mid-November -- to announce details of the test showing that melanoma patients treated with allovectin fared worse than patients treated with conventional chemotherapy. Only 4.6 percent of patients treated with allovectin reported that their tumors shrank, compared to 12.3 percent of chemotherapy patients.
“Prolonging this study by delaying the analysis caused undue harm to patients,” Feuerstein wrote. “That's disgusting, inexcusable behavior.”
But Vical continues to try to develop new drugs. With its stock currently valued at $1.02, the company on Tuesday announced initial tests of a proposed treatment for genital herpes and last week began phase 2 testing on a proposed vaccine for organ transplant patients, in partnership with Tokyo’s Astellas Pharma Global Development.
"We are very pleased with the collaborative nature of our relationship with Astellas and with the progress being made," Samant said at the time.
Feuerstein’s other four nominees for worst CEO were Joe Zakrzewski of Amarin (Nasdaq: AMRN), Harvey Berger of Ariad Pharmaceuticals (Nasdaq: ARIA), John Johnson of Dendreon (Nasdaq: DNDN) and Tuan Ha Ngoc of Aveo Pharmaceuticals (Nasdaq: AVEO). Samant won with 71 percent of the 14,140 votes cast by Feuerstein's readers.
BS) – Nearly two dozen cases of the potentially deadly H1N1 flu virus have been confirmed in the Chicago area, CBS 2 has learned.
Finding the flu virus among patients at Loyola University Medical Center in Maywood is keeping special machines working overtime right now. Seven patients at Loyola tested positive for Influenza A on Christmas Eve. Five of them had the H1N1 strain known as swine flu.
They’ve detected a sudden burst of the 2009 swine flu spreading right here in the Chicago area. Microbiologist Paul Schreckenberger says last week alone, 21 patients tested positive for Influenza A. All but one of those cases were the 2009 H1N1 swine flu.
“We don’t know why it’s emerging,” Schreckenberger says.
He says people may have gotten a false sense of security over the last couple of flu seasons, which were comparatively mild.
In Texas, the rush is on for flu shots. The very flu shots that Texans Dustin Wright, and his wife, Ashley, never received.
Dustin was hit with H1N1 flu strain, or swine flu, and he died Dec. 5.
“You don’t think it will happen to you,” Ashley says.
H1N1 is causing 80 percent of the flu infections this year. It’s the same strain that triggered a nationwide pandemic in 2009. But at that time, it was new. Now, it’s not, and the current flu vaccine offers protection.
“That really is, in terms of prevention and protection, the best method, in terms of reducing transmission or spread of influenza,” Rush University Medical Center physician Alexander Tomich says.
But remember, it takes two weeks after you get the shot to build up the anti-bodies that provide protection from the flu. So, the earlier you get it the better.
According to the Centers for Disease Control, less than half of all Americans get a flu shot each
This is a question for the thinkers that used to gather here in mass as opposed to the current crop of yaks who have nothing to discuss.
Which would move the stock and validate Vical the best, news that Bristol Meyer Squib is using Vaxfectin in the next generation of their cancer immunotherapies or the news that a major pharma has licensed CyMVectin to go after the universal vaccine against birth defects?
Insider buying dipped last week as we recorded records for executive team members and directors for 62 companies. Perhaps, the early week volatility scared them back to the boardroom?
Anyway, today we highlight a company that meets a number of our favorite criteria.
Insiders switched from selling to buying
Cluster buying from multiple executives
Unusually large tickets
Previous history of "getting it right"
Last week, four insiders at Vical Incorporated (NASDAQ:VICL) purchased 580,000 shares for a total investment of $823,600.
[Related -Vical (VICL) Licenses Vaxfectin Adjuvant For Use In Malaria Vaccines To Cyvax]
Vical researches and develops biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of serious or life-threatening diseases.
The Company has three active independent clinical and preclinical development programs in the areas of infectious disease and cancer, including a fully enrolled Phase III clinical trial using its Allovectin immunotherapeutic in patients with metastatic melanoma; a completed preclinical program, with an allowed investigational new drug application, using its CyMVectin prophylactic vaccine formulated with its Vaxfectin adjuvant to prevent cytomegalovirus, infection before and during pregnancy, and a preclinical program with therapeutic and prophylactic vaccines for herpes simplex virus type II formulated with its Vaxfectin adjuvant.
[Related -Stocks Jump As Fed Acts To Spur Growth; Equinix (EQIX) Surges]
All four have a remarkably similar Vical history of selling or buying for $0.01 per share. Last week's activity was the first time that any of the quartet – or any other team members for that matter – purchased VICL shares. All the other activity was selling or acquiring shares for a penny.
Although there were four buyers, we are going to focus on the biggest. Chief Executive Officer, President, Acting Chief Financial Officer and Director, Mr. Vijay B. Samant stepped up and bought 330,000 shares at $1.42 for a total sales price of $468,600. That's close to half of his annual pay of $921,000. Would you put half your pre-tax income into any stock idea without having intimate knowledge of the inner workings and prospects?
Prior to last week, we counted 12 Samant Vical sales and one non-open market purchase of 84,600 shares at a penny (the rich getting richer). That's why his January purchase stands out. Depositing some cash into VICL is in direct contrast to the ATM, cash withdrawal role the stock has played for the CEO.
At the end of 2013, the company was at various phase 1 and 2 studies with the FDA. Based on insider transaction rules, we would not expect to hear much in the way of news until the late spring/early summer at the earliest. However, that doesn't mean that our quarter of buyers isn't privy to results and data on the trials to date.
With the quartet's history of cashing out, the recent cluster of buying is a matter of connecting the dots. The change of heart has to be taken seriously.